Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 10—October 2021
Research Letter

Emergence of SARS-COV-2 Spike Protein Escape Mutation Q493R after Treatment for COVID-19

Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla Gasperina, Andreina BajComments to Author , and Fabrizio Maggi
Author affiliations: Pisa University Hospital, Pisa, Italy (D. Focosi); Azienda Socio-Sanitaria Territoriale, Varese, Italy (F. Novazzi, F. Dentali, A. D. Dalla Gasperina, A. Baj, F. Maggi); University of Insubria, Varese, (A. Genoni, F. Dentali, D. Dalla Gasperina, A. Baj, F. Maggi)

Cite This Article

Abstract

We report in vivo selection of a severe acute respiratory syndrome coronavirus 2 spike mutation (Q493R) conferring simultaneous resistance to bamlanivimab and etesivimab. This mutation was isolated from a patient who had coronavirus disease and was treated with these drugs.

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) usually result from random mutations in humans or other hosts, but accelerated evolution can also occur under selective pressure from therapeutic interventions using neutralizing antibodies (1). Bamlanivimab has been recently withdrawn as a monotherapy because of treatment failure against E484K SARS-CoV-2 virus variants. Emergency use remains authorized for the bamlanivimab/etesevimab cocktail, targeting overlapping epitopes (2), for which no completely resistant variant has been reported to date. This cocktail has been effective in reducing hospitalizations when administered early after infection (3).

Given increasing reports of accelerated intrahost evolution of drug-resistant SARS-CoV-2 clades after neutralizing antibody‒based treatments (4,5), we began screening patients who failed to show virus-negative results for nasopharyngeal swab (NPS) specimens after they were given bamlanivimab/etesevimab. We report an in vivo case of a spike protein escape mutation conferring combined resistance to bamlanivimab and etesevimab.

A 73-year-old man had cholangiocarcinoma diagnosed during February 2021. While he was waiting for chemotherapy, sepsis developed, and he was admitted to Varese Hospital (Varese, Italy) on April 12 and given a steroid and antimicrobial drugs. At admission, reverse transcription PCR (RT-PCR) for SARS CoV-2 in an NPS specimen showed a negative result, but the same test showed a positive result on April 24.

Given that he had recovered from sepsis, the patient was moved to the coronavirus disease unit of the hospital on April 25. He satisfied 1 of the frail-patient categories for emergency use of spike protein monoclonal antibodies approved by the Italian Drug Agency. The patient was also seronegative for S1/S2 IgG against spike protein (Diasorin, https://www.diasorin.com).

On April 26, the patient received a single intravenous infusion of bamlanivimab (700 mg) and etesevimab (400 mg) at the hospital. RT-PCR performed on an NPS specimen collected before the infusion was positive for SARS-CoV-2 and showed a cycle threshold (Ct) of 12 (Alinity Analyzer; Abbott Laboratories, https://www abbott.com).

Follow-up analysis of NPS specimens showed positive results on Apr 28 (Ct 15) and May 3 (Ct 24). Chest computed tomography on April 30 showed progression to interstitial pneumonia, and the patient was given noninvasive ventilation. No additional bamlanivimab/etesevimab infusion was performed, and the patient died on May 14.

According to national guidelines for breakthrough infections, we sequenced SARS-CoV-2‒positive samples. We performed a SARS CoV-2 RT-PCR on NPS specimens by using the Alinity Platform (Abbott Laboratories), and measured S1/S2 IgG by using a chemiluminescent immunoassay (Diasorin). We used the Sanger method to sequence the spike gene as reported (6), analyzed sequences by using NextStrain (https://nextstrain.org), and deposited sequences in GenBank.

Figure

Evolution of SARS-CoV-2 variants in a patient who had coronavirus disease who was given bamlanivimab and etesivimab, Italy. Ct, cycle threshold; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure. Evolution of SARS-CoV-2 variants in a patient who had coronavirus disease who was given bamlanivimab and etesivimab, Italy. Ct, cycle threshold; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Spike gene sequencing of the NPS specimen obtained on April 24 clade B.1.1.7 (Alpha; NextStrain clade 20I/501Y.V1; GenBank accession no. MZ157261), which was 94% prevalent in Italy at that time. However, the May 3 specimen showed a secondary A1478G peak in the spike protein gene, corresponding to the spike Q493R mutation, which became predominant by May 8 (Ct 18; GenBank accession no. MZ157275) (Figure).

E484, F490, Q493, and S494 are the 4 aa residues within the spike protein receptor-binding motif that are known to be critical for bamlanivimab binding. Q493 is also among the many more receptor-binding motif residues crucial for interactions with etesivimab. Q493R/K (which can be selected in vitro by bamlanivimab [7,8]) is to date the only mutation that causes resistance to bamlanivimab and etesivimab. This residue also causes resistance to other class 3 monoclonal antibodies (8) (i.e., those that do not overlap with the angiotensin-converting enzyme 2 binding site and have accessibility to the receptor-binding domain epitope in the up and down conformations).

In pseudoviral neutralization assays, Q493R reduces susceptibility to bamlanivimab by >6,666-fold, to etesevimab by 232-fold, and to the combination of both drugs by >100-fold (2). In a flow cytometry competitive assay, Q493R reduces the 50% inhibitory concentration >100-fold for bamlanivimab and 42-fold for etesivimab (7). Q493R has a frequency of 0.006% in the GISAID database (https://www.gisaid.org; 85 of 1,424,998 deposited sequences as of May 8, 2021; https://covid19dashboard.regeneron.com/?tab=Mutation_Details&subTab=Spike), making the occurrence of co-infection with a Q493R-positive strain extremely unlikely in our patient.

It remains unclear how such risk extends to different spike protein monoclonal antibody cocktails targeting nonoverlapping epitopes. Although different mutations can similarly cause immune escape by the nonoverlapping REGN-CoV-2 (imdevimab plus casirivimab) cocktail, hamster models and clinical trials showed no increased emergence of variants (R. Copin et al., Regeneron Pharamaceuticals Inc., pers. comm., 2021 Jun 22). Nevertheless, Choi et al. reported a patient having detectable SARS-CoV-2 for 154 days, and accelerated viral evolution in the spike protein after being given remdesivir and REGN-CoV-2 (4).

The nonoverlapping AZD7442 (COV2–2130 and COV2–2196) cocktail also seems resistant to rapid escape (J. Dong et al., Huazhong University of Science and Technology, pers. comm., 2021 Jun 21), but again, such in vitro or animal models could miss rare in vivo events.

In conclusion, SARS-CoV-2 mutations conferring resistance to bamlanivimab and etesevimab can arise in vivo after specific selective pressure; Q493 mutations increase binding affinity to the angiotensin-converting enzyme 2. Additional studies are needed to clarify whether such escape mutations can spread and persist in humans. Genomic surveillance for SARS-CoV-2 variants is encouraged for coronavirus disease patients who do not respond well to treatment with spike protein monoclonal antibodies.

Dr. Focosi is a medical research scientist at Pisa University Hospital, Pisa, Italy. His research interests are clinical immunology and emerging viral infections, including diagnostics and neutralizing antibody-based therapeutics.

Top

References

  1. Jensen  B, Luebke  N, Feldt  T, Keitel  V, Brandenburger  T, Kindgen-Milles  D, et al. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021;8:100164. DOIPubMedGoogle Scholar
  2. US Food and Drug Administration. Emergency use authorization (EUA) for bamlanivimab 700 mg and estevimab 1,400 mg IV administered together. Center for Drug Use and Evaluation (CDER), 2021 [cited 2021 Jul 22]. https://www.fda.gov/media/145802/download
  3. Matthews  DB. A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol. 2020;20:591. DOIPubMedGoogle Scholar
  4. Choi  B, Choudhary  MC, Regan  J, Sparks  JA, Padera  RF, Qiu  X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:22913. DOIPubMedGoogle Scholar
  5. Hensley  MK, Bain  WG, Jacobs  J, Nambulli  S, Parikh  U, Cillo  A, et al. Intractable COVID-19 and prolonged SARS-CoV-2 replication in a CAR-T-cell therapy recipient: a case study. Clin Infect Dis. 2021;ciab072.
  6. Maggi  F, Novazzi  F, Genoni  A, Baj  A, Spezia  PG, Focosi  D, et al. Imported SARS-COV-2 variant P.1 detected in traveler returning from Brazil to Italy. Emerg Infect Dis. 2021;27:124951. DOIPubMedGoogle Scholar
  7. European Medicines Agency. Assessment report Eli Lilly. Company Limited use of bamlanivimab and etesevimab for the treatment of COVID-19, 2021 [cited 2021 Jun 2]. https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-limited-antibody-combination-bamlanivimab/etesevimab-covid19-article-53-procedure-assessment-report_en.pdf
  8. Starr  TN, Greaney  AJ, Dingens  AS, Bloom  JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2:100255. DOIPubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2710.211538

Original Publication Date: July 27, 2021

Table of Contents – Volume 27, Number 10—October 2021

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Andreina Baj, University of Insubria, Via Dunant 5, Varese 21100, Italy

Send To

10000 character(s) remaining.

Top

Page created: July 23, 2021
Page updated: September 19, 2021
Page reviewed: September 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external